BRIEF-Immunovaccine announces dosing of first patient in Phase 1B clinical trial for DPX-Survivac

Thu Sep 8, 2016 7:23am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

Sept 8 (Reuters) - Immunovaccine Inc

* Survivac in combination with Incyte's IDO1 enzyme inhibitor Epacadostat Source text for Eikon: Further company coverage: